![]() |
市场调查报告书
商品编码
1498656
全球炭疽疫苗市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测Global Anthrax Vaccine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
预计到2032年,全球炭疽疫苗市场需求将从2023年的167.3亿美元达到近281.6亿美元的市场规模,2024-2032年研究期间的复合年增长率为5.96%。
炭疽疫苗是一种生物製剂,可提供针对引起炭疽的炭疽桿菌的免疫力。它主要用于高暴露风险的个人,例如军事人员、实验室工作人员和处理动物产品的个人。该疫苗以免疫系统为目标,产生针对细菌保护性抗原的抗体,从而提供针对感染的防御。它是生物防御和职业健康计划的重要组成部分。
生物恐怖主义和生物战的持续威胁,加上炭疽自然爆发的可能性,凸显了炭疽疫苗接种作为公共卫生防范措施的至关重要性。这提高了人们对炭疽作为潜在生物安全威胁的认识,促使政府机构和国防组织储存炭疽疫苗并投资疫苗接种计划,从而提振了市场需求。疫苗开发和製造技术的进步促进了下一代炭疽疫苗的开发,其安全性得到改善,功效增强,剂量方案减少,从而推动了市场的采用和扩张。此外,增加政府对生物防御计划和新出现的传染病的资助和研究拨款,透过支持疫苗研究和开发工作来刺激市场成长。
此外,不断扩大的全球旅行和贸易网络增加了炭疽传播和传播的风险,推动了高风险地区和高风险族群(例如军事人员、急救人员和实验室工作人员)对炭疽疫苗的需求。此外,製药公司、政府机构和研究机构之间的策略伙伴关係和合作促进了疫苗生产的可扩展性、监管审批和全球分销,从而促进了市场成长。然而,潜在的副作用和有限的意识可能会挑战未来几年的市场成长。
研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外,这些工具也对全球炭疽疫苗市场的各个细分市场进行了包容性评估。炭疽疫苗产业的成长和趋势为本研究提供了整体方法。
炭疽疫苗市场报告的这一部分提供了国家和区域层面细分市场的详细资料,从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。
本节涵盖区域前景,重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲炭疽疫苗市场当前和未来的需求。此外,该报告重点关注所有主要地区各个应用领域的需求、估计和预测。
该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。炭疽疫苗市场的主要参与者包括Altimmune Inc.、Agrovet、Bayer AG、Bavarian Nordic、Biogenesis Bago SA、Ceva Sante Animale、Colondo Serum Company、Emergent BioSolutions、Elusys Therapeutics Inc.、IndianImmunologicals Ltd.、Solutions、Elusys Therapeutics Inc.、IndianImmunologicals Ltd.、Intervac (PVT) Ltd、 JOVAC、Merck Co Inc.、Proton Biopharma Ltd。和其他发展。
如果您有任何客製化要求,请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。
The global demand for Anthrax Vaccine Market is presumed to reach the market size of nearly USD 28.16 Billion by 2032 from USD 16.73 Billion in 2023 with a CAGR of 5.96% under the study period 2024-2032.
The anthrax vaccine is a biological preparation that provides immunity against Bacillus anthracis, which causes anthrax. It is primarily used for individuals at high risk of exposure, such as military personnel, laboratory workers, and individuals handling animal products. The vaccine targets the immune system to generate antibodies against the bacterium's protective antigen, thereby providing defense against infection. It is a crucial component in biodefense and occupational health programs.
The persistent threat of bioterrorism and biological warfare, coupled with the potential for natural outbreaks of anthrax, underscores the critical importance of anthrax vaccination as a public health preparedness measure. This heightened awareness of anthrax as a potential biosecurity threat drives government agencies and defense organizations to stockpile anthrax vaccines and invest in vaccination programs, bolstering market demand. Advancements in vaccine development and manufacturing technologies have led to the development of next-generation anthrax vaccines with improved safety profiles, enhanced efficacy, and reduced dosage regimens, driving market adoption and expansion. Additionally, increasing government funding and research grants for biodefense initiatives and emerging infectious diseases stimulate market growth by supporting vaccine research and development efforts.
Moreover, expanding global travel and trade networks increase the risk of anthrax transmission and dissemination, driving demand for anthrax vaccines in high-risk regions and among at-risk populations, such as military personnel, first responders, and laboratory workers. Furthermore, strategic partnerships and collaborations between pharmaceutical companies, government agencies, and research institutions facilitate vaccine production scalability, regulatory approvals, and global distribution, fostering market growth. However, potential side effects and limited awareness may challenge the market growth in the coming years.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Anthrax Vaccine. The growth and trends of Anthrax Vaccine industry provide a holistic approach to this study.
This section of the Anthrax Vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Anthrax Vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Anthrax Vaccine market include Altimmune Inc., Agrovet, Bayer AG, Bavarian Nordic, Biogenesis Bago SA, Ceva Sante Animale, Colondo Serum Company, Emergent BioSolutions, Elusys Therapeutics Inc., Indian Immunologicals Ltd., Intervac (PVT) Ltd, JOVAC, Merck Co Inc., Proton Biopharma Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.